Showing papers by "Janet B. W. Williams published in 2014"

TL;DR: Both vabicaserin doses were well tolerated with no significant safety signals and no weight gain, and the 200 mg/day group achieved proof of concept using central ratings.

TL;DR: The results of this study suggest that effects of monitoring as measured within each site are complex, at least in early stages of implementing such a monitoring procedure and at a highly experienced clinical site such as that of Kahn and colleagues.